Aspirin for Prevention of Preeclampsia

被引:0
|
作者
A. Atallah
E. Lecarpentier
F. Goffinet
M. Doret-Dion
P. Gaucherand
V. Tsatsaris
机构
[1] University Hospital Center,Hospices Civils de Lyon, Department of Obstetrics and Gynecology, Femme Mère Enfant Hospital
[2] Claude-Bernard University Lyon1,Assistance Publique
[3] University Hospital Center Cochin Broca Hôtel Dieu,Hôpital de Paris, Department of Obstetrics and Gynecology, Port
[4] Groupe Hospitalier Universitaire Ouest,Royal Maternity
[5] Université Paris Descartes,PRES Sorbonne Paris Cité
[6] PremUP Foundation,undefined
[7] DHU Risques et Grossesse,undefined
来源
Drugs | 2017年 / 77卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Aspirin is currently the most widely prescribed treatment in the prevention of cardiovascular complications. The indications for the use of aspirin during pregnancy are, however, the subject of much controversy. Since the first evidence of the obstetric efficacy of aspirin in 1985, numerous studies have tried to determine the effect of low-dose aspirin on the incidence of preeclampsia, with very controversial results. Large meta-analyses including individual patient data have demonstrated that aspirin is effective in preventing preeclampsia in high-risk patients, mainly those with a history of preeclampsia. However, guidelines regarding the usage of aspirin to prevent preeclampsia differ considerably from one country to another. Screening modalities, target population, and aspirin dosage are still a matter of debate. In this review, we report the pharmacodynamics of aspirin, its main effects according to dosage and gestational age, and the evidence-based indications for primary and secondary prevention of preeclampsia.
引用
收藏
页码:1819 / 1831
页数:12
相关论文
共 50 条
  • [31] Prevention of preeclampsia with aspirin is dependant on bleeding time increase
    Dumont, A
    Beaufils, M
    Flahaut, A
    Verdy, E
    Uzan, S
    AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (04) : 21A - 21A
  • [32] Aspirin in the prevention of preeclampsia: the conundrum of how, who and when
    Shanmugalingam, Renuka
    Hennessy, Annemarie
    Makris, Angela
    JOURNAL OF HUMAN HYPERTENSION, 2019, 33 (01) : 1 - 9
  • [33] PREVENTION OF PREECLAMPSIA WITH LOW-DOSE ASPIRIN - REPLY
    SIBAI, BM
    NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (11): : 795 - 795
  • [34] Aspirin for preeclampsia prevention: does diet play a role?
    Gulersen, Moti
    Rochelson, Burton
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2022, 226 (04) : 595 - 596
  • [35] Assessment of Racial Disparities in Aspirin Prophylaxis for Preeclampsia Prevention
    Ragunanthan, Nina W.
    Lamb, Jordan
    Hauspurg, Alisse
    Beck, Stacy
    AMERICAN JOURNAL OF PERINATOLOGY, 2024, 41 (05) : 635 - 640
  • [36] Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia
    Tolcher, Mary Catherine
    Chu, Derrick M.
    Hollier, Lisa M.
    Mastrobattista, Joan M.
    Racusin, Diana A.
    Ramin, Susan M.
    Sangi-Haghpeykar, Haleh
    Aagaard, Kjersti M.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2017, 217 (03) : 365.e1 - 365.e8
  • [37] Randomised controlled trial of ketanserin and aspirin in prevention of preeclampsia
    Steyn, DW
    Odendaal, HJ
    LANCET, 1997, 350 (9087): : 1267 - 1271
  • [38] Aspirin in the prevention of preeclampsia: the conundrum of how, who and when
    Renuka Shanmugalingam
    Annemarie Hennessy
    Angela Makris
    Journal of Human Hypertension, 2019, 33 : 1 - 9
  • [39] Can nitric oxide replace aspirin in prevention of preeclampsia?
    Ohl, J
    BettaharLebugle, K
    Dellenbach, P
    CONTRACEPTION FERTILITE SEXUALITE, 1996, 24 (04): : 259 - 261
  • [40] Pharmacokinetics of low-dose aspirin for the prevention of preeclampsia
    Mkhize, P. Z.
    Dorsamy, V.
    Bagwandeen, C.
    Khaliq, O. P.
    Moodley, J.
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2025, 305 : 423 - 424